Teva Pharmaceutical Indus Bolsa (NYSE: TEVA)

Teva Pharmaceutical Indus (NYSE:TEVA) Bolsa

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Equities

News

Markets

Tech

General

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

TSLA

Stanley Druckenmiller vendió todas sus acciones en Broadcom tras su alza del 100% y reforzó su inversión en grandes tecnológicas.

El nuevo giro de Druckenmiller: vende Broadcom y amplía su apuesta en tecnológicas clave

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

<ul>
<li>Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2</li>
<li>Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period1,2</li>
<li>Injection adherence remained high throughout the study (~90%), while over 75% of patients completed the study duration1</li>
</ul>

Teva's Final PEARL Study Data Confirm AJOVY's Sustained Migraine Prevention And Favorable Safety Over Two Years

EMA's CHMP Recommended Granting Marketing Authorization For Teva's Austedo For The Treatment Of Adults With Moderate-to-severe Tardive Dyskinesia

Goldman Sachs has initiated coverage of generic pharmaceutical stocks, highlighting the sector's strong long-term <a href="https://www.benzinga.com/general/health-care">potential despite recent volatility</a>. 
Analyst Matt Dellatorre points to a mix of company-specific challenges—such as fiscal 2025 guidance—and broader industry concerns like tariffs and drug pricing. 
Still, he argues that many of these stocks are attractively valued and represent businesses well-positioned for growth.
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45819356/dogecoin-down-10-on-the-week-is-the-musk-trump-spat-bearish-for-doge">Dogecoin Down 10% On The Week: Is The Musk-Trump Spat Bearish For DOGE?</a>
<h2 class="wp-block-heading">Teva Pharmaceutical </h2>
Goldman Sachs has initiated Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating, with a <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $24</a>. 
Dellatorre sees an improvement in the core business, with an upside to consensus EBITDA estimates driven by strong growth in the branded segment.
On the generics side, Goldman Sachs expects limited growth over the next few years as an expanding biosimilar portfolio. Other new product launches are offset by the Revlimid settlement expiration in 2026.
The analyst expects robust growth on continued momentum for key assets on the branded side, acknowledging the industry-wide Part D re-design hit to <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" rel="noreferrer noopener">2025 growth and margins</a>.
Goldman views Teva&#8217;s biosimilar portfolio as an important long-term growth driver for the generics business. The company now has 10 in-line assets and 13 biosimilars in the pipeline. 2027 expects five potential launches in the U.S. and three in the EU/exUS.
Teva expects biosimilar revenue of around $400 million in fiscal 2024 to double by fiscal 2027.
Goldman writes that Teva&#8217;s branded pipeline represents a significant valuation lever. It sees a favorable catalyst path over the next 24 months. The analyst sees an attractive catalyst path, with multiple opportunities to re-rate as these pipeline assets are de-risked.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" rel="noreferrer noopener">Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars</a>
<h2 class="wp-block-heading">Viatris</h2>
Dellatorre initiated Viatris Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) with a Neutral rating and <a href="https://www.benzinga.com/quote/VTRS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>. Why? There&#8217;s a lack of clarity on the growth outlook for the core business given current structural dynamics in the generics and branded segments.
More specifically, on the generics side, <a target="_blank" href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" rel="noreferrer noopener">excluding Indore</a>, Goldman is optimistic about recent underlying trends and continues to monitor Viatris&#8217; ability to meaningfully offset price erosion via new product launches and progress on the ongoing portfolio optimization.
In the branded drugs segment, the analyst writes that older products losing market share in the U.S. and Asia have hurt growth, and it is watching for signs of recovery. However, there have been signs of stabilization in developed markets, China, and other emerging markets in recent quarters. Despite the decline, these products still generate steady cash, and Goldman is observing how the company reinvests this into new growth opportunities.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45175642/drug-maker-amneal-highlights-strong-commercial-uptake-for-parkinsons-drug-but-q1-earnings-are-mixed" rel="noreferrer noopener">Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson&#8217;s Drug But Q1 Earnings Are Mixed</a>
<h2 class="wp-block-heading">Amneal Pharmaceuticals&nbsp;</h2>
Goldman initiated Amneal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) with a Buy rating and a <a href="https://www.benzinga.com/quote/AMRX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $12</a>.
The analyst is optimistic about the growth outlook for Amneal&#8217;s core business. He cites a strong product pipeline and track record of execution through various market environments.
Goldman has confidence in Amneal&#8217;s ability to continue to offset typical price erosion via new product launches. Amneal also has structural tailwinds as the company aggressively shifts its focus toward higher-value products.
In the branded segment, analyst Dellatorre is positive on the ongoing launch of the next-generation <a target="_blank" href="https://www.benzinga.com/25/04/44673049/amneals-combination-drug-shows-improved-sleep-quality-in-parkinsons-disease-patients" rel="noreferrer noopener">Parkinson&#8217;s disease drug</a> Crexont to ultimately offset Rytary&#8217;s 2025 loss of exclusivity and the endocrinology franchise&#8217;s stable growth outlook.
Price Action: TEVA stock is up 1.39% at $17.49, AMRX stock is up 2.37% at $7.34, and VTRS stock is up 2.07% at $8.64 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45800081/dr-reddys-and-alvotech-join-hands-to-develop-biosimilar-for-mercks-blockbuster-cancer-drug" target="_blank" rel="noreferrer noopener">Dr Reddy&#8217;s And Alvotech Join Hands To Develop Biosimilar For Merck&#8217;s Blockbuster Cancer Drug</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Large Cap

Health Care

Price Target

Initiation

Analyst Ratings

AMRX

VTRS

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

Goldman Sachs analyst Matt Dellatorre initiates coverage on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating and announces Price Target of $24.

Goldman Sachs Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $24

Teva Pharmaceutical Indus's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) short percent of float has risen 36.14% since its last report. The company recently reported that it has 38.70 million shares sold short, which is 3.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teva Pharmaceutical Indus Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749128429_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teva Pharmaceutical Indus has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teva Pharmaceutical Indus's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teva Pharmaceutical Indus's peer group average for short interest as a percentage of float is 3.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Teva Pharmaceutical Indus?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$175.00</td>
<td>$36.9K</td>
<td>10</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.00</td>
<td>$25.4K</td>
<td>49.9K</td>
<td>898</td>
</tr>
<tr>
<td>SRDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$190.0K</td>
<td>502</td>
<td>500</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$310.00</td>
<td>$43.5K</td>
<td>3.0K</td>
<td>494</td>
</tr>
<tr>
<td>AKBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.50</td>
<td>$31.0K</td>
<td>438</td>
<td>350</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$88.3K</td>
<td>576</td>
<td>217</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$710.00</td>
<td>$63.4K</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$87.5K</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$120.00</td>
<td>$35.6K</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $1420.0 per contract. There were 10 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• For TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on June 20, 2025. This event was a transfer of 750 contract(s) at a $18.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.4K, with a price of $34.0 per contract. There were 49987 open contracts at this strike prior to today, and today 898 contract(s) were bought and sold. 
• Regarding SRDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), we observe a call option trade with bullish sentiment. It expires in 72 day(s) on August 15, 2025. Parties traded 500 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $190.0K, with a price of $380.0 per contract. There were 502 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 44 day(s) on July 18, 2025. Parties traded 38 contract(s) at a $310.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $43.5K, with a price of $1145.0 per contract. There were 3038 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding AKBA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), we observe a call option trade with bullish sentiment. It expires in 226 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 438 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $88.3K, with a price of $883.0 per contract. There were 576 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 198 day(s) on December 19, 2025. This event was a transfer of 5 contract(s) at a $710.00 strike. The total cost received by the writing party (or parties) was $63.4K, with a price of $12690.0 per contract. There were 25 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be neutral, expiring in 226 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $115.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $87.5K, with a price of $8753.0 per contract. There were 12 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be neutral, expiring in 471 day(s) on September 18, 2026. This event was a transfer of 5 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $7130.0 per contract. There were 0 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AKBA

MRNA

SRDX

9 Health Care Stocks Whale Activity In Today's Session

<ul>
<li>Real-world claims studies evaluating UZEDY&#xAE; (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options</li>
<li>Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to date</li>
<li>As a leader in neuroscience, Teva is committed to researching and developing long-acting treatment options that help address unmet needs for individuals living with schizophrenia</li>
</ul>

Reported Friday, Teva Showcases Real-World UZEDY Data Demonstrating Lower Relapse Rates, Better Adherence, And Reduced Healthcare Use Compared To Oral Antipsychotics

Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) hosted 2025 Innovation &amp; Strategy Day on Thursday to launch the acceleration phase of its &#8220;Pivot to Growth&#8221; strategy and to discuss portfolio priorities.
The company outlined its plan to evolve into a leading biopharmaceutical company, emphasizing its innovative medicines franchise and a strong generics and biosimilars portfolio.
President and CEO Richard Francis said the company is entering a new chapter focused on scaling its innovative medicines franchise while maintaining strength in generics and biosimilars.
Francis highlighted that Teva has completed Phase 1 of its "Pivot to Growth" plan, achieving nine consecutive <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45666576/teva-reaffirms-pivot-to-growth-strategy-progress-with-launch-of-acceleration-phase-at-2025-innovat" rel="noreferrer noopener">quarters of growth</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a>
The company's innovative medicines portfolio, including Austedo, Ajovy, and Uzedy, generated over $2.3 billion in 2024 revenue.
Teva's generics business has also rebounded, with a 5% increase in revenue across regions and a top-three global portfolio that may yield five new product launches by 2027.
&#8220;The past two years have been about returning to growth&#8230;Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio,&#8221; Francis said.
Teva aims to build a $5 billion innovative medicines franchise by 2030, led by its key assets and a strong late-stage pipeline.
Austedo is expected to surpass $2.5 billion in sales by 2027 and reach over $3 billion by 2030. Ajovy is in 43 countries, with additional launches expected this year. Uzedy has rapidly captured over 60% of the risperidone long-acting injectable (LAI) market, and the upcoming olanzapine LAI is expected to expand Teva's footprint in schizophrenia treatment.
The late-stage pipeline includes promising assets such as duvakitug for inflammatory bowel disease, DARI for asthma, and emrusolmin for Multiple System Atrophy, each carrying multibillion-dollar peak sales potential.
TEV-‘408, an anti-IL-15 antibody for celiac disease, has received FDA fast-track status and could exceed $1 billion in peak sales.
Teva's generics, biosimilars, and over-the-counter (OTC) segments remain critical revenue drivers.
The company has 13 biosimilars in development, with five launches planned by 2027. Its $1.1 billion OTC business continues to outperform the market with double-digit growth, while ongoing manufacturing transformations aim to improve competitiveness and margins.
Teva reaffirmed its 2027 financial targets, including a 30% operating margin, more than $2.7 billion in free cash flow, and over $700 million in savings from operational efficiencies.
Price Action: TEVA stock is trading lower by 3.55% to $17.55 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45670275/build-a-bear-sticks-to-outlook-despite-tariff-pressure-stock-soars-25" target="_blank" rel="noreferrer noopener">Build-A-Bear Sticks To Outlook Despite Tariff Pressure, Stock Soars 25%</a></li>
</ul>
Photo via Shutterstock

Movers

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030

Teva Provides Updates Ahead Of Its Innovation and Strategy Day; Say sInnovative Medicines Franchise On Track To Exceed $5B By 2030, Reaffirms 2027 Financial Targets

In the last three months, 4 analysts have published ratings on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Teva Pharmaceutical Indus and provided 12-month price targets. The average target is $22.5, accompanied by a high estimate of $25.00 and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 5.49% from the previous average price target of $21.33.
<img src="https://www.benzinga.com/files/images/story/2025/1748466040_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Teva Pharmaceutical Indus by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teva Pharmaceutical Indus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teva Pharmaceutical Indus analyst ratings.</a>
<h2>Unveiling the Story Behind Teva Pharmaceutical Indus</h2>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Understanding the Numbers: Teva Pharmaceutical Indus's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Teva Pharmaceutical Indus's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.89% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 5.5%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Teva Pharmaceutical Indus's ROE excels beyond industry benchmarks, reaching 3.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.71, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Teva Pharmaceutical Indus Stands With Analysts

Truist Securities analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating and announces Price Target of $25.

Truist Securities Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $25

Teva Pharmaceutical Industries Announces That FDA Granted Fast Track Designation For Investigational TEV-53408, An Anti-IL-15 Antibody, For The Treatment Of People With Celiac Disease On A Gluten-Free Diet; TEV-53408 Is Currently Being Evaluated In A Phase 2a Trial To Assess The Efficacy And Safety In Adults With Celiac Disease

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">lymphopoietin) and IL-13</a>.
Teva has an exclusive license to develop BD9 for TH2-driven inflammatory diseases such as <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45615937/teva-and-biolojic-design-initiate-ind-enabling-studies-of-bd9-a-multibody-designed-to-explore-the-" rel="noreferrer noopener">atopic dermatitis and asthma</a>.&nbsp;
By simultaneously blocking two key drivers of TH2-driven inflammation, BD9 can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma, where current treatments fall short.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a>
The initiation of IND-enabling studies marks a critical milestone in translating this scientific innovation into a potential therapeutic option. It will pave the way for clinical trials and ultimately bring hope to underserved patient populations.
Under the terms of their agreement, Teva is developing BD9 worldwide.
In exchange, Biolojic is eligible to receive milestone payments based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones, including the initiation of IND-enabling studies.
In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;Johnson &amp; Johnson's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
In January, The U.S. Food and Drug Administration (FDA) issued a warning regarding the risk of anaphylaxis, a rare but severe allergic reaction associated with glatiramer acetate, a medication used to treat relapsing <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43174108/fda-warns-of-severe-allergic-reaction-risk-with-tevas-multiple-sclerosis-drug" rel="noreferrer noopener">forms of multiple sclerosis (MS)</a>.
Glatiramer acetate, sold under the brand name Copaxone by&nbsp;Teva and as generics like Glatopa, is an injectable medication designed to reduce the frequency of MS relapses.
In February, Axsome Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) signed a settlement agreement with&nbsp;Teva Pharmaceuticals.
The settlement resolves all patent litigation related to Axsome's Auvelity (dextromethorphan HBr –&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">bupropion HCl) product</a>.
Auvelity is approved in the U.S. for major depressive disorder.
The litigation resulted from Teva submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Auvelity in the U.S. before the expiration of applicable Axsome patents.
Price Action: TEVA stock is up 6.01% at $17.98 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a></li>
</ul>
Photo via Shutterstock

Contracts

ALVO

AXSM

Why Is Teva Stock Trading Higher On Tuesday?

WIIM

Teva Pharmaceutical Industries shares are trading higher after the company along with Biolojic Design initiated IND-enabling studies of BD9.

Teva And Biolojic Design Initiate IND-Enabling Studies Of BD9

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) to approximately $2.25 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) (the "Total Maximum Amount").
Teva is also increasing the Pool Tender Caps applicable to the Pool 2 Notes and the Pool 3 Notes (each, as defined below) from $250.0 million (equivalent) to $350.0 million (equivalent) and from $200.0 million (equivalent) to $350.0 million (equivalent), respectively, in each case representing aggregate cash purchase price (exclusive of accrued and unpaid interest).&nbsp;

Teva Pharma Upsizes Debt Tender Offer To $2.25B, Expands Pool 2 & Pool 3 Caps To $350M Each

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully&nbsp;upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the "Notes"). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the "Tender Offer") to purchase, for cash, its 3.150% Senior Notes due 2026, 4.750% Sustainability-Linked Senior Notes due 2027, 3.750% Sustainability-Linked Senior Notes due 2027, 7.875% Sustainability-Linked Senior Notes due 2029, 7.375% Sustainability-Linked Senior Notes due 2029 and 8.125% Sustainability-Linked Senior Notes due 2031&nbsp;(as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.
The Notes consist of (i) Teva Pharmaceutical Finance Netherlands II B.V's ("Teva Finance II") €1,000,000,000 aggregate principal amount of 4.125% EUR-denominated Senior Notes maturing in 2031, (ii) Teva Pharmaceutical Finance Netherlands III B.V.'s ("Teva Finance III") $500,000,000 aggregate principal amount of 6.000% USD-denominated Senior Notes maturing in 2032 and (iii) Teva Pharmaceutical Finance Netherlands IV B.V.'s ("Teva Finance IV" and, together with Teva Finance II and Teva Finance III, the "Issuers") $700,000,000 aggregate principal amount of 5.750% USD-denominated Senior Notes maturing in 2030.
The settlement of the Notes is expected to occur on or about May 28, 2025, subject to customary closing conditions. The settlement of the Notes will satisfy the financing condition to the Tender Offer.

Offerings

Teva Pharmaceutical Industries Announces It Upsized Its Offering From $2B And Priced ~$2.3B Of Its Senior Notes

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it has commenced tender offers (the "Offers") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the "Total Maximum Amount") of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
<ul>
<li>USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Pool 1 Notes");</li>
<li>USD 4.750% Sustainability-Linked Senior Notes due 2027, CUSIP 88167AAP6 / ISIN US88167AAP66 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 2 Notes");</li>
<li>EUR 3.750% Sustainability-Linked Senior Notes due 2027, Common Code 240660709 / ISIN XS2406607098 (Registered), issued by Teva Pharmaceutical Finance Netherlands II B.V. (the "Priority 3 Notes" and together with the Priority 2 Notes, the "Pool 2 Notes");</li>
<li>USD 7.875% Sustainability-Linked Senior Notes due 2029, CUSIP 88167AAS0 / ISIN US88167AAS06 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 4 Notes");</li>
<li>EUR 7.375% Sustainability-Linked Senior Notes due 2029, Common Code 259280443 / ISIN XS2592804434 (Registered), issued by Teva Pharmaceutical Finance Netherlands II B.V. (the "Priority 5 Notes"); and</li>
<li>USD 8.125% Sustainability-Linked Senior Notes due 2031, CUSIP 88167AAR2 / ISIN US88167AAR23 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 6 Notes," and together with the Priority 4 Notes and the Priority 5 Notes, the "Pool 3 Notes," and the Pool 3 Notes, together with the Pool 1 Notes and the Pool 2 Notes, the "Notes").</li>
</ul>

Buybacks

Teva Launches $2 Billion Bond Buyback to Cut Debt Across Multiple Note Series

Teva Pharmaceuticals (NYSE and TASE: TEVA)&nbsp;today announced that Moody's Investor Services ("Moody's") has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Teva Pharmaceuticals Announced That Moody's Investor Services Has Raised The Company's Corporate Credit Rating To Ba1, Outlook Stable From Ba2, Outlook Positive

Teva Pharmaceuticals shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $21 to $23.

Press Releases

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva Reaffirms "Pivot to Growth" Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

IPOs

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

COLL

NTRB

NTRBW

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Perrigo

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Verona Pharma plc - American Depositary Shares

Comments

Teva Pharmaceutical Indus

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL